Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena

ABSTRACT: Proteomics analysis of matched tumor and normal adjacent tumor regions of 40 patients with multiparametric magnetic resonance imaging (mpMRI) visible or invisible tumors. All patients have clinically significant intermediate-risk (pathological ISUP Grade Group 2), localized prostate cancer.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Dr. Thomas Kislinger

PROVIDER: MSV000088000 | MassIVE | Wed Aug 18 11:14:00 BST 2021

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The Proteogenomic Landscape of Curable Prostate Cancer

Project description:Proteogenomic analysis of 76 patients with clinically relevant intermediate-risk, localized prostate cancer.

| MSV000081552 | MassIVE

Proteomic and phosphoproteomic analysis of prostate cancer

Project description:The present study had a total of 125 primary prostate cancer samples collected with paired non-tumor adjacent lung tissues from the treatment-naïve Chinese patients and proteogenomic analysis was performed.

2024-02-07 | PXD049446 |

Prostate cancer progression: From non-malignant to bone metastasisProstate cancer progression: From non-malignant to bone metastasis

Project description:Proteome characterization of gland confined prostate tumors and non-malignant prostate tissue. Whole cell protein extracts were purified from FFPE radical prostatectomy specimens for a total of 28 tumor samples and 8 adjacent non-malignant prostate tissues. Associated ProteomeXchange identifiers: PXD003430, PXD003452, PXD003515, PXD004132, PXD003615, PXD003636. Quantitative proteomic analysis of adjacent non-malignant prostate tissue (n=8) and gland confined prostate tumors (n=28) obtained from radical prostatectomy procedures; and bone metastatic prostate tumors (n=22) obtained from patients operated to relief spinal cord compression. At the time of surgery, most metastatic patients had relapsed after androgen-deprivation therapy, while 5 were previously untreated.

2018-08-21 | PXD009868 | Pride

Expression data from LCM captured prostate cancer cells

Project description:The prostate represents a complex mix of cell types and there is a need to analyze distinct cell populations to better understand their potential interactions. This study of cell-type specific gene expression patterns will contribute to understanding of how tumor epithelial cells may be affected by adjacent interstitial stromal cells within the tumor microenvirnonment. LCM and microarray analysis were used to identify gene expression patterns in prostate cancer epithelial and interstitial stromal cell populations. More than 500 genes whose expression levels were significantly different in epithelial cells versus adjacent stromal tissue were identified. Several chemokines and growth factors were more highly expressed in prostate cancer stromal cells while several transcription factors and receptors were more highly expressed in epithelial cells. Five micron serial sections from three different intermediate grade prostate tumors were provided. One section from each had been stained by hematoxylin and eosin and the tumor areas marked for identification. To obtain RNA from 2 different tissue types (glandular epithelium and interstitial stroma) tumor areas observed to have abundant cells of interest were identified. Tumor epithelium and adjacent stromal tissue were collected separately from each slide. We sought to obtain similar populations of cells of each tissue type, so to that end, we examined each slide and and marked areas to direct the laser capture. Approximately 1,000 cells were captured per cap and RNA was extracted and hybridized to Affymetrix microarrays as recommended by manufacturer.

2010-04-10 | E-GEOD-20758 | biostudies-arrayexpress

Copy number alteration burden predicts prostate cancer relapse: Agilent 1M aCGH data for human primary prostate cancer samples

Project description:Prostate cancer is the most common malignancy in men. Yet, the modest benefit of treatment highlights the unmet need for prognostic biomarkers in prostate cancer (1). Few large prostate oncogenome resources currently exist that combine the molecular and clinical outcome data necessary for prognostic discovery. To determine the extent to which genomic aberrations reflect the risk of prostate cancer-specific outcomes, we profiled more than 100 primary prostate cancers with long-term follow-up for genome-wide copy number alterations (CNA). We also updated the long-term clinical outcome (median 8 years) of an additional independent cohort of 181 primary prostate cancers that we previously profiled for CNA and expression changes (2). Together, we found that CNA burden across the genome, defined as the percent of the tumor genome affected by CNA, is prognostic for recurrence and metastasis in these two cohorts. This prognostic significance of CNA is independent of Gleason grade, a major existing histopathological prognostic variable in prostate cancer. Moreover, in intermediate-risk Gleason 7 prostate cancers that show a wide range of outcomes, CNA burden is also prognostic for biochemical recurrence, independent of prostate-specific antigen or nomogram score. CNA burden therefore has the potential to stratify patients by their risk of recurrence in an otherwise intermediate risk subpopulation. We further demonstrate that CNA burden can be established in diagnostic FFPE needle biopsies using low-input whole genome sequencing. Together, this work highlights the potential of oncogenomics to identify useful and clinically amenable prognostic factors that may inform prostate cancer outcome and treatment. Human prostate samples were profiled on Agilent 1M aCGH arrays per manufacturer's instructions. A pooled reference normal DNA was used as the reference.

2014-06-30 | E-GEOD-54691 | biostudies-arrayexpress

Homo sapiens

Project description:Genomic Evaluation of Multiparametric Magnetic Resonance Imaging -visible and -nonvisible Lesions in Clinically Localized Prostate Cancer

| PRJNA395907 | ENA

The proteome of localized prostate cancer, part 6

2016-06-01 | PXD003636 | Pride

The proteome of localized prostate cancer, part 2

2016-06-01 | PXD003452 | Pride

The proteome of localized prostate cancer, part 5

2016-06-01 | PXD003615 | Pride

The proteome of localized prostate cancer, part 4

2016-06-01 | PXD004132 | Pride